NASDAQ · QSI

Quantum-Si incorporated

Healthcare · Medical - Devices

$0.76▲ 1.45% ($0.01)at close

Pre-market$0.76▼ 0.11%5:42 AM ET

52-week

$0.69$3.10

Market cap

$149.53M

P/E

-1.63

EPS (TTM)

-$0.45

Next earnings

Nov 4, 2026

No multiple

What the market price implies · Reverse DCF

To support a price of $0.76, this model requires revenue to grow by 57.95%/yr over the next 10 years, compounded annually.

Historical revenue grew by 50.05%/yr over the past 2 years. The required annual growth rate is 7.90 percentage points higher.

Selected forecast · Base scenario

17.82%/yr · actual 10-year annualized revenue growth

Year 1 growth: 29.8%

Market-implied · Base operating assumptions + edited margins

57.95%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.76

Estimated value / share

$0.52

Base scenario

This estimate is 31.73% below the price used.

USD · TTM ending 2026-06-30

Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 29.8% · Ending margin 0% · Discount rate 18.54%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 9:58 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -55.53%Revenue (TTM): -52.96%FCF (TTM): 2.84%

What changed

The stock fell 55.53% over the last year. Revenue declined 52.96% over the trailing twelve months. Operating margin moved from -3,242.53% to -5,929.72%. Free cash flow grew 2.84% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Operating margin stands at -5,929.72%. Revenue declined 52.96% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection.

CEOJeffrey Alan Hawkins

SectorHealthcare

IndustryMedical - Devices

Employees145

IPO dateNov 13, 2020

https://www.quantum-si.com

Market multiples

Forward P/E—

EV/EBITDA-2.15

Enterprise value$200.07M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-41.79%

Gross margin (FY2025)47.33%▼5.0ppvs FY2024

Operating margin (FY2025)-3,996.72%▼446.2ppvs FY2024

ROE-49.11%▼2.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$1.90▲151.36%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est -$0.13 · Revenue est $280K

View

NASDAQ · QSI

Quantum-Si incorporated

Healthcare · Medical - Devices

$0.76▲ 1.45% ($0.01)at close

Pre-market$0.76▼ 0.11%5:42 AM ET

52-week

$0.69$3.10

Market cap

$149.53M

P/E

-1.63

EPS (TTM)

-$0.45

Next earnings

Nov 4, 2026

No multiple

What the market price implies · Reverse DCF

To support a price of $0.76, this model requires revenue to grow by 57.95%/yr over the next 10 years, compounded annually.

Historical revenue grew by 50.05%/yr over the past 2 years. The required annual growth rate is 7.90 percentage points higher.

Selected forecast · Base scenario

17.82%/yr · actual 10-year annualized revenue growth

Year 1 growth: 29.8%

Market-implied · Base operating assumptions + edited margins

57.95%/yr · flat 10-year annualized revenue growth

Valuation

Recommended · Revenue & margin DCF

Price used

$0.76

Estimated value / share

$0.52

Base scenario

This estimate is 31.73% below the price used.

USD · TTM ending 2026-06-30

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 29.8% · Ending margin 0% · Discount rate 18.54%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 9:58 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -55.53%Revenue (TTM): -52.96%FCF (TTM): 2.84%

What changed

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Performance

Return analysis

Company profile

Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection.

CEOJeffrey Alan Hawkins

SectorHealthcare

IndustryMedical - Devices

Employees145

IPO dateNov 13, 2020

https://www.quantum-si.com

Market multiples

Forward P/E—

EV/EBITDA-2.15

Enterprise value$200.07M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-41.79%

Gross margin (FY2025)47.33%▼5.0ppvs FY2024

Operating margin (FY2025)-3,996.72%▼446.2ppvs FY2024

ROE-49.11%▼2.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$1.90▲151.36%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est -$0.13 · Revenue est $280K

View